---
title: "Esophageal Cancer Treatment"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
editor: visual
bibliography: zotero.bib
---

## Lymphadenectomy

Retrospective data from Japan in the 1980's suggested superior survival after extended lymphadenectomy for gastric cancer.

Extent of lympadenectomy can be categorized:

D1: Perigastric D2: Central nodes + splenic hilum D2$\alpha$: Central nodes D3: Extended nodes

## D1 Perigastric nodes

Lymph node stations immediately adjacent to the stomach

-   1:
-   2:
-   3: Lesser curvature
-   4: Greater curvature
-   5: Suprapyloric
-   6: Infrapyloric

## D1 Perigastric Nodes

![](https://deidt7p41jzcy.cloudfront.net/songun-gr1_lrg_D1_1980.png)

## D2 Central Nodes + splenic hilum

Lymph nodes adjacent to celiac axis:

-   12a: Left side of porta hepatis
-   8: Common hepatic artery
-   7: Left gastric artery
-   9: Celiac axis
-   11: Proximal splenic artery
-   10: Splenic hilum

## D1$\alpha$ Central Nodes

Lymph nodes adjacent to celiac axis:

-   12a: Left side of porta hepatis
-   8: Common hepatic artery
-   7: Left gastric artery
-   9: Celiac axis
-   11: Proximal splenic artery
-   ~~10: Splenic hilum~~

## D2 Central Nodes

![](https://deidt7p41jzcy.cloudfront.net/songun-gr1_lrg_D2_1980.png)

## Durch Trial: D2 vs D1 Lymphadenectomy


![](https://deidt7p41jzcy.cloudfront.net/songun-gr2_lrg.gif)

## Durch Trial: Overall Survival


![](https://deidt7p41jzcy.cloudfront.net/songun-gr3_lrg.jpg)
## Durch Trial: D2 vs D1 Lymphadenectomy


![](https://deidt7p41jzcy.cloudfront.net/songun-gr3_lrg.jpg)

## Durch Trial: Cause of Death


![](https://deidt7p41jzcy.cloudfront.net/songun-gr4_lrg.jpg)

## Durch Trial: Disease-free Survival


![](https://deidt7p41jzcy.cloudfront.net/songun-gr5_lrg.jpg)

## Durch Trial: D2 vs D1 Lymphadenectomy


![](https://deidt7p41jzcy.cloudfront.net/songun-gr3_lrg.jpg)

## Dutch Trial: D2 vs D1 

Operative mortality higher with D2 (10% vs 4%)

More complications wtih D2 (43% vs 25%)

More reoperations with D2 (18% vs 8%)

## Dutch Trial: Total vs Subtotal gastrectomy

Protocol did not dictate extend of gastric resection, but did require a proximal margin of 5cm if a subtotal gastrectomy performed.

No difference in survival between total vs subtotal gastrectomy

## Dutch Trial: Conclusions

D2 lymphadenectomy is associated with better local control of gastric cancer than D1 node dissection, but at an increased risk of mortality and complications.

Can the toxicity of extended lymphadenectomy be reduced?

- Elimination of splenectomy (D1$\alpha$)
- Mininally-invasive techniques

## MAGIC Trial - Perioperative Chemotherapy

503 gastric cancer stage II adenocarcinoma of stomach, GE juncction or lower esophagus

ECF Chemo $\rightarrow$ Surgery $\rightarrow$ ECF Chemot
vs
Surgery alone

Chemotherapy: Epirubicin, ciplatin, 5FU

Surgery 3-6 weeks after last dose of chemo
Chemo 6-12 weeks after surgery

## MAGIC - Perioperative Chemotherapy

Tumor Location

- Gastric 74%
- GE junction 11%
- Distal esophagus 15%

## MAGIC- Perioperative Chemotheray
Curative radical resection 79% with chemo vs. 70$ (p=0.03)

Longer 5-year survival wtih chemo (36% vs 23%). p=0.0009

Complete chemotherapy regimen (6 doses) in only 42%

Of patients who completed preop chemotherapy and surgery, only 34% received postoperative chemotherapy.

## FLOT - Perioperative Chemotherapy

7616 patients with adenocarcinoma of GE junction or stomach randomized:

ECF $\rightarrow$ Surgery $\rightarrow$ ECF
vs 
FLOT $\rightarrow$ Surgery $\rightarrow$

Longer survival with FLOT (median 50 months vs 35 months)

## TOPGEAR

ECF $\rightarrow$ Surgery $\rightarrow$ ECF $\rightarrow$ ChemoRT
vs
ECF $\rightarrow$ Surgery $\rightarrow$ ECF

## HIPEC - Ongoing Trials

GASTRICHIP:^[@glehen1]

Patients with peritoneal diseae ftrom gastro cancer. 

Chemo $\rightarrow$ Surgery with cytoreduction $\rightarrow$ Chemo
vs
Chemo $\rightarrow$ Surgery with cytoreduction + HIPEC $\rightarrow$ Chemo

## GASTRICHIP ^ [@glehen1]

105 patients randomized 2014 - 2018. Trial closed due to slow accrual

55 patient treatment stopped prior to cytoreductive surgery due to disease progression

HIPEC with mitomycin and ciplatin for 60min at 42ÂªC.

Median survival 15 months in both groups (without a difference).

## PERISCCOPE-II^[@koemans1]

Comparison of cytoreductive surgery + HIPIC to systemic chemotherapy in patients with gastric cancer and peritoneal metastasis.


## CHIMERA Trial

FLOT + HIPIC vs FLOT + Surgery in advanced gastric cancer 78

## PREVENT^[@gotze1]

Diffuse-type gastric and GE junction adenocarcnoma:

FLOT $\rightarrow$ Gastrectomy + HIPIC $\rightarrow$
vs
FLOT $\rightarrow$ Gastrectomy $\rightarrwo$

